The outperformance echoes that of other companies such as Johnson & Johnson and NuVasive. After falling sharply in April, procedure volumes steadily improved in May and June. In the end, TAVR sales in the U.S. suffered a low-teens decline, with other geographies faring slightly better. In response, Edwards said it expects to hit the top end of its -5% to +5% full-year range for TAVR sales. Investors responded favorably to the results, sending shares in Edwards up 5% in after-hours trading.